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Background: The aim of this randomized controlled study was to determine whether octreotide (OCT) or
scopolamine butylbromide (SB) was the more effective antisecretive drug controlling gastrointestinal (GI)
symptoms due to malignant bowel obstruction (MBO) caused by advanced ovarian cancer.
Methods: Ninety-seven advanced ovarian cancer patients with inoperable MBO were randomized to OCT
0.3 mg/day (OCT group, n = 48) or SB 60 mg/day (SB group, n = 49) for 3 days through a continuous
subcutaneous infusion. The following parameters were measured: episodes of vomiting, nausea, dry mouth,
drowsiness, and continuous and colicky pain, using a Likert scale corresponding to a numerical value (none 0,
slight 1, moderate 2, severe 3) recorded before starting the treatment (T0) and 24 h (T1), 48 h (T2), and 72 h
after (T3) and the daily quantity of GI secretions through the Nasogastric tube (NGT) during the period of
study. One patient in the SB group is not included in any assessments since she withdrew consent prior to
receiving any treatment because of rapidly progressing cancer.
Results: OCT significantly reduced the amount of GI secretions at T1, T2, and T3 (P < 0.05) compared with SB.
NGT secretions significantly reduced at T1, T2, and T3 compared with T0 (P < 0.05) in the OCT group, while in
the SB group, only at T3, NGT secretions significantly reduced compared with T0. OCT treatment induced a
significantly rapid reduction in the number of daily episodes of vomiting and intensity of nausea compared
with SB treatment. No significant changes were observed in dry mouth, drowsiness, and colicky pain after
either drug. Continuous pain values were significantly lower in the OCT group than in the SB group at T2
and T3 (P < 0.05).
Conclusions: At the doses used in this study, OCT was more effective than SB in controlling gastrointestinal
symptoms of bowel obstruction. Further studies are necessary to understand the role of hydration more
clearly in such a clinical situation.
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Ovarian cancer is the sixth most common cancer among
women worldwide [1]. As the surgical treatment of gyne-
cologic cancer becomes more sophisticated and chemo-
therapeutic approaches become more effective, patients’
prognoses have improved with respect to the duration of
their disease-free state. However, when cancer does recur
and effective treatment options have been exhausted, the
focus of management shifts from curative intent to palli-
ation of symptom manifestations and complications [2].
Malignant bowel obstruction (MBO) is the most common
and distressing complication in patients with advanced or
recurrent ovarian cancer with an incidence of about 15%–
35% [3,4].
Etiologies of MBO in ovarian cancer include extrinsic
occlusion of the lumen, malignant infiltration of bowel
muscles or nerves, carcinomatosis with involvement
of mesentery, and abdominal or pelvic postoperative or
tumoral adhesions [4]. Secondary intestinal immobility
resulting from opioids and certain antiemetics also plays a
role in MBO [3]. MBO results in an accumulation of gas-
tric, pancreatic, and biliary secretions; reduced absorption
of water and sodium; and an increase in water and so-
dium secretion because of increased gastric distension.
This pathophysiology results in vomiting, nausea, pain,
esophagitis, constipation, and/or diarrhea. Once bowel ob-
struction has occurred, the median life expectancy drops
to approximately 4 months [5]. Although these patients’
survival time may be short, their suffering remains great.
Understanding and treating the signs and symptoms of
MBO in ovarian cancer patients require urgent attention.
Many patients are unfit for surgery or further chemo-
therapy and radiotherapy due to the presence of diffuse
intraperitoneal carcinomatosis, multiple partial bowel
obstruction points, ascites, and/or previous radiotherapy,
or because of their poor overall functional status. The
aim of any further treatment is to relieve the symptoms
related to bowel obstruction and improve the quality
of life (QoL). Conservative treatment of inoperable MBO
has been found to be effective in controlling the distres-
sing symptoms [6]. In particular, the administration of
nasogastric tube (NGT) and liquid supplementation has
proved to be effective in controlling gastrointestinal symp-
toms caused by bowel obstruction [6]. However, pro-
longed NGT is not recommended because of common
complications, such as mucosal erosion and hemorrhage,
esophagitis, and aspiration pneumonia, which seriously
affect QoL in inoperable MBO patients [7].
Drug treatment without NGT, such as analgesics, anti-
emetics, and antisecretory drugs, is successful in most
patients [8]. To reduce gastrointestinal (GI) secretions,
two classes of antisecretory drugs are used: anticholiner-
gics, such as scopolamine butylbromide (SB), and som-
atostatin (SMS) analogs, such as octreotide (OCT). Thetwo drugs have different mechanisms. The anticholiner-
gic activity of SB decreases the tonus and peristalsis in
smooth muscle, both by competitive inhibition of mus-
carinic receptors at the smooth muscle level and by
impairment of ganglionic neural transmission in the
bowel wall [9,10]. SB can also reduce intestinal secretions
because of muscarinic cholinergic receptors on mucosal
cells of the intestinal lumen and in human salivary glands
[9,10]. OCT, as an analog of SMS, modulates gastrointes-
tinal function by reducing gastric acid secretion, slowing
intestinal motility, decreasing bile flow, increasing mucous
production, and reducing splanchnic blood flow [11,12].
However, there have been no comparative studies con-
cerning the efficacy and safety of SB and OCT in redu-
cing symptoms and gastrointestinal secretions in bowel
obstructed patients with advanced ovarian cancer in
China. Accordingly, we conducted the first clinical study
to compare the efficacy of SB and OCT for the control
of nausea/vomiting in patients with MBO who were un-
likely to respond to any other therapy.
Methods
Patients
This study was a prospective clinical trial at Department
of general surgery, Qilu Hospital of Shandong University
between January 2010 and December 2013. It was ap-
proved by the Ethics Committee of Qilu Hospital. All
study participants provided written informed consent
before randomization.
Inclusion criteria included a diagnosis of documented
recurrence of ovarian cancer and the presence of a bowel
obstruction based on a compilation of clinical signs, symp-
toms, and/or radiographic evidence. Available oncologic
therapies for tumor control had been exhausted for these
patients. The obstruction could not be surgically correct-
able, as assessed by the patient’s gynecologic oncology
surgeon. Furthermore, patients must have had a life
expectancy greater than 2 months and ability to give a
written informed consent. The following were excluded:
(1) patients having already undergone treatment with the
drugs under study; (2) patients with cognitive failure; (3)
patients with a current history of diabetes mellitus, pan-
creatitis, or active biliary disease.
Treatment
After informed consent was obtained, eligible patients
were randomized to the OCT group or the SB group.
Randomization was achieved by means of computer-
generated random numbers. The trial flow chart is showed
in Figure 1.
NGT was introduced, and all the patients were man-
aged with intravenous fluids in order to restore the loss
of fluid and electrolytic balance. Commonly, as much as
3.5 l of isotonic saline solution was required if the
Figure 1 Trial flow chart.
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ably less if such signs were absent. Energy is provided by
glucose solutions and vitamins (vitamins B6, C, and K),
Coenzyme A and adenosine triphosphate are necessary
as supplements as they are essential for the maintenance
of normal metabolic function. After the patient has formed
adequate urine, potassium chloride would be added to
the infusion. Pain therapy was carried out concurrently
according to the World Health Organization (WHO)
guidelines [13]. From T0 to T3, the patients were not
given steroids, antiemetics, anticholinergics, H2 blockers,
or omeprazole.
Patients in the OCT group and SB group were given
OCT (Sandostatin, Novartis Pharma Stein AG) 0.3 mg
or SB (Boehringer Ingelheim Pharma GmbH & Co.KG)
60 mg daily by a continuous subcutaneous infusion. These
dosages were extrapolated by previous experience [9,14].
If signs of intolerance such as hypotension, hypertension,
chest pain, shortness of breath, or anaphylactic reaction
occurred, patients were removed from the study and re-
ceived no further OCT or SB.
Data collection
Age and performance status according to the ECOG
scale were evaluated for all patients. Episodes of vomiting
were recorded. The intensity of the following symptoms
was evaluated: nausea, dry mouth, drowsiness, and con-
tinuous and colicky pain. All symptoms were assessed
through a Likert scale corresponding to a numerical value:
0 = none, 1 = slight, 2 =moderate, 3 = severe. All thesymptoms were recorded before starting the treatment
(T0), 24 h (T1), 48 h (T2), and 72 h (T3). Moreover, we
recorded the daily quantity of GI secretions through the
NGT.
Data analysis
Differences between the two treatment groups were
assessed using a χ2 test or Fisher’s exact test for categor-
ical variables. A non-parametric test, the Mann–Whitney
U-test was used for continuous variables. The Wilcoxon
signed ranks test was used to compare the data at different
times. A P value less than 0.05 was considered statistically
significant. Statistical Package for Social Scientists (SPSS,
version 18.0, IL) was used for all analyses.
The data were analyzed only for the 3-day study period.
After 3 days, researchers were free to change to the alter-
nate drug, to administer SB and OCT in association, to
carry on with the same treatment if it proved efficacious,
or to increase the dosages of OCT or SB.
Results
Patient characteristics
Ninety-seven patients with advanced ovarian cancer and
MBO were randomly assigned to the OCT and SB groups.
One patient in the SB group is not included in any assess-
ments since she withdrew consent prior to receiving any
treatment because of rapidly progressing cancer. There-
fore, 96 patients were assessed in the final analysis. There
were 48 patients in the OCT group and 48 patients in the
SB group. There were no significant differences between
Table 2 Daily quantity of GI secretions through the NGT
(ml, mean ± SD)
NGT secretions OCT group SB group
T0 1,515.1 ± 401.2 1,486.2 ± 432.4
T1 563.6 ± 315.1§* 1,206.9 ± 278.2
T2 355.4 ± 205.4§* 808.5 ± 312.6
T3 298.5 ± 189.2§* 783.4 ± 258.6*
*P < 0.05 for comparison with T0; §P < 0.05 for comparison between groups.
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of ovarian cancer as assessed by CT scanning, number of
previous operations, and predominant symptoms by pa-
tient report (Table 1).
Treatment outcome
All patients showed well tolerance to OCT or SB. At T0,
no significant difference of NGT secretions was showed
between the OCT and SB groups (1,515.1 ± 401.2 VS.
1,486.2 ± 432.4 ml, P > 0 05, Table 2). At T1, T2, and T3,
NGT secretions in the OCT group were significantly less
than that in the SB group (T1: 563.6 ± 315.1 VS. 1,206.9 ±
278.2, P < 0.05; T2: 355.4 ± 205.4 VS. 808.5 ± 312.6; P <
0.05; T3: 298.5 ± 189.2 VS. 783.4 ± 258.6, P < 0.05, Table 2).
In the OCT group, NGT secretions significantly reduced
at T1, T2, and T3 compared with T0 (P < 0.05), while in
the SB group, only at T3, NGT secretions significantly re-
duced compared with T0 (Table 2).
At T1 and T2, the number of episodes of vomiting in
the OCT group was significantly less than that in the SB
group (P < 0.05). Significant reductions in the number of
episodes of vomiting were evidenced in the OCT group
at T1, T2, and T3 (P < 0.05), whereas the reduction was
significant only at T3 in the SB group (P < 0.05) (Table 3).
Significant reduction in the intensity of nausea was re-
ported in the OCT group at T2 and T3 (P < 0.05), while
no differences were found in the SB group. The intensity
of nausea was significantly lower in the OCT group than
that in the SB group at T2 and T3 (P < 0.05; Table 3).
No significant changes were observed in dry mouth, drow-

















Liver metastasis 7 5
More than one site 20 18
Predominant symptoms 0.677
Nausea and vomiting 46 44
Bloating 20 16 0.399
Constipation 16 19 0.525
Abdominal pain 35 29 0.194values were significantly lower in the OCT group than in
the SB group at T2 and T3 (P < 0.05, Table 3).
Discussion
MBO is a challenging complication of advanced ovarian
cancer. Administration of analgesic, antisecretive, and
antiemetic drugs has proved to be a valid method of
controlling the symptoms of inoperable MBO. Many
studies have documented the efficacy of SB and OCT in
MBO patients with advanced cancer [7-9,15,16]. The re-
sults of our study confirm the capacity of both drugs to
reduce GI secretions in patients with inoperable MBO
and advanced ovarian cancer. At the doses used in this
study, OCT turned out to be more effective than SB in
controlling vomiting, although these differences tended
to be less pronounced after 3 days. Thus, OCT seems to
have a shorter onset of activity than SB, which requires
some days before giving a significant effect. About sea-
sickness and continuous pain, we also observed the ef-
fect of the OCT is superior to SB probably as the result
of a reduction in gastrointestinal secretions and gastric
distension, mainly inducing nausea and continuous pain.Table 3 Episodes of vomiting, nausea, dry mouth,
drowsiness, colicky pain and continuous pain, symptom
distress score
Symptom Group Point in treatment
T0 T1 T2 T3
Vomiting OCT 5.8 ± 0.6 1.5 ± 0.3* 0.5 ± 0.3* 1.2 ± 0.5*
SB 5.4 ± 0.8 4.1 ± 0.7§ 2.3 ± 0.6§ 2.0 ± 0.8*
Nausea OCT 2.5 ± 0.4 1.5 ± 0.1 0.3 ± 0.3* 0.2 ± 0.1*
SB 2.8 ± 0.5 1.3 ± 0.4 1.2 ± 0.4§ 1.0 ± 0.3§
Dry mouth OCT 2.1 ± 0.1 1.8 ± 0.3 1.9 ± 0.2 1.8 ± 0.1
SB 1.9 ± 0.2 2.6 ± 0.4 2.7 ± 0.3 2.5 ± 0.4
Drowsiness OCT 1.6 ± 0.3 1.7 ± 0.2 1.6 ± 0.2 2.0 ± 0.3
SB 1.7 ± 0.2 1.8 ± 0.1 1.5 ± 0.3 1.7 ± 0.3
Colicky pain OCT 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.2 0.4 ± 0.1
SB 0.5 ± 0.2 0.4 ± 0.1 0.4 ± 0.3 0.3 ± 0.1
Continuous pain OCT 1.7 ± 0.2 0.9 ± 0.4 0.5 ± 0.3 0.6 ± 0.3
SB 1.9 ± 0.1 1.4 ± 0.3 1.3 ± 0.1§ 0.7 ± 0.1§
Data are expressed as mean ± SD.
*P < 0.05 for comparison with T0; §P < 0.05 for comparison between groups.
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fluid secretion in bowel obstruction depends on vaso-
active intestinal peptide (VIP)-induced inflammatory
events [17]. OCT has been shown to have a potent anti-
VIP effect resulting in the inhibition of intestinal secre-
tion [18].
Parenteral hydration use in the care of terminal cancer
patients is still a controversial topic [19]. The main goal
of hydration is considered to meet the water/electrolyte
baseline requirements and to correct or prevent symp-
toms related to dehydration, such as thirst, dry mouth,
altered mental status, drowsiness, constipation, postural
hypotension, and asthenia [20]. However, anecdotal ex-
perience has revealed that hydration may serve as a fuel
for an obstructed bowel and increase the risk of vomit-
ing [16]. Moreover, Burge et al. [21] showed that patients
with advanced cancer receiving less fluid than 750 ml/
day do not experience much more thirst than those re-
ceiving more than 750 ml/day. Bruera et al. [22] found
no significant differences between the hydration group
and the placebo group in four dehydration symptoms
and concluded that hydration at 1 l per day did not im-
prove symptoms, quality of life, or survival compared
with placebo. Further studies are necessary to make ad-
vantages and disadvantages of hydration in such circum-
stances clearer.
Although all patients in our study received enough
parenteral hydration, some patients underwent intoler-
able dry mouth, especially in the SB group. Dry mouth is
a subjective feeling of mouth dryness and is not always
accompanied by a detectable decrease in salivation [8].
One of the causes of dry mouth is nasal blockage caused
by NGT leading to fluid loss from rapid evaporation due
to breathing through the mouth. The second reason is
reduction of mastication which plays an important role
in the regulation of salivary secretion by the effects me-
diated through somatic afferent nerves of the oral mu-
cosa and in the periodontal tissues. Moreover, SB can
produce dry mouth because of the muscarinic receptors
in human salivary glands which can explain why patients
on SB had a trend toward greater dry mouth intensity.
The study may have some limitations owing to the
small number of enrollable patients. Moreover, we de-
signed the trial for a 3-day period only because of the
patients’ poor conditions, which could worsen daily and
create further problems in determining therapeutic effi-
cacy. Furthermore, our study did not include a crossover
study which asks for a washout period between the two
different treatments, and this is not recommended in pa-
tients with advanced cancer.
Conclusions
In conclusion, in inoperable MBO, OCT was found to
be more effective than SB in relieving gastrointestinalsymptoms of advanced ovarian cancer patients. There-
fore, OCT should be considered as a first-choice antise-
cretive drug. Further, well-designed studies are necessary
to better evaluate the role of parenteral hydration, not
only in symptom control but also regarding a possible
influence in increasing GI secretions in patients with inop-
erable MBO. Moreover, it would be interesting to evaluate
the time required to remove the NGT on administering
OCT and SB from the beginning of the treatment of MBO
patients.
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